Stock Events

Stock Events

Brickell Biotech 

$2.12
32
-$0.23-9.79% Thursday 04:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-1.51
-0.9
-0.29
0.32
Expected EPS
N/A
Actual EPS
N/A

Financials

-303.93%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
6.94MRevenue
-21.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Journey Medical
DERM
Mkt Cap213.64M
Dermira, acquired by Eli Lilly, focuses on dermatological treatments, including excessive sweating, directly competing with Brickell's pipeline.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers a broad range of dermatology treatments, including for conditions that overlap with Brickell Biotech's focus areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse portfolio that includes dermatology and skin condition treatments, competing with Brickell's product offerings.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the dermatology market, including products that could rival Brickell's.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a presence in the dermatology sector, offering treatments that could compete with Brickell Biotech's developments.
Novartis
NVS
Mkt Cap237.61B
Novartis offers dermatology products and has a strong pipeline in skin conditions, posing competition to Brickell Biotech.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, with its acquisition of Allergan, has a strong dermatology portfolio, including treatments for conditions targeted by Brickell.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a focus on biologics in various therapeutic areas, including dermatology, which could compete with Brickell's biotech solutions.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on innovative biologic treatments, including for dermatological conditions, competing with Brickell's research and products.

About

Health Technology
Biotechnology
Pharmaceuticals: Major
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 30 full-time employees. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
Show more...
CEO
Robert Brown
Employees
13
Country
US
ISIN
US10802T1051
WKN
000A3DMHL

Listings

0 Comments

Share your thoughts

FAQ

What is Brickell Biotech stock price today?▼
The current price of BBI is $2.12 USD — it has decreased by -9.79% in the past 24 hours. Watch Brickell Biotech stock price performance more closely on the chart.
What is Brickell Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Brickell Biotech stocks are traded under the ticker BBI.
What is Brickell Biotech revenue for the last year?▼
Brickell Biotech revenue for the last year amounts to 6.94M USD.
What is Brickell Biotech net income for the last year?▼
BBI net income for the last year is -21.1M USD.
How many employees does Brickell Biotech have?▼
As of April 04, 2026, the company has 13 employees.
In which sector is Brickell Biotech located?▼
Brickell Biotech operates in the Manufacturing sector.
When did Brickell Biotech complete a stock split?▼
The last stock split for Brickell Biotech was on July 05, 2022 with a ratio of 1:45.
Where is Brickell Biotech headquartered?▼
Brickell Biotech is headquartered in Boulder, US.